影像学技术作为肾细胞癌的预测和预后生物标志物。
Imaging techniques as predictive and prognostic biomarkers in renal cell carcinoma.
机构信息
Mount Vernon Cancer Centre - Medical Oncology, Rickmansworth Road, Northwood, Middlesex HA6 2RN, UK.
出版信息
Ther Adv Med Oncol. 2013 Mar;5(2):119-31. doi: 10.1177/1758834012463624.
Abstract
A number of imaging modalities are showing promise as predictive and prognostic biomarkers in advanced renal cell carcinoma. This review discusses progress to date in this exciting area and identifies areas of future promise.
摘要
多种影像学方法在晚期肾细胞癌的预测和预后生物标志物方面显示出前景。本文讨论了这一令人兴奋领域的最新进展，并确定了未来有希望的领域。
相似文献
1
Imaging techniques as predictive and prognostic biomarkers in renal cell carcinoma.
Ther Adv Med Oncol. 2013 Mar;5(2):119-31. doi: 10.1177/1758834012463624.
2
Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma.
Nat Rev Urol. 2023 Mar;20(3):133-157. doi: 10.1038/s41585-022-00676-0. Epub 2022 Nov 21.
3
Diagnostic and prognostic molecular markers in renal cell carcinoma.
J Urol. 2008 Jun;179(6):2096-102. doi: 10.1016/j.juro.2008.01.083. Epub 2008 Apr 18.
4
Predictive markers in advanced renal cell carcinoma.
Semin Oncol. 2013 Aug;40(4):459-64. doi: 10.1053/j.seminoncol.2013.05.001.
5
Biomarkers of renal cell carcinoma.
Urol Oncol. 2014 Apr;32(3):243-51. doi: 10.1016/j.urolonc.2013.07.011. Epub 2013 Nov 13.
6
Prognostic factors of renal cell carcinoma.
Rozhl Chir. 2022 Fall;101(10):469-477. doi: 10.33699/PIS.2022.101.10.469-477.
7
Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Dan Med J. 2017 Oct;64(10).
8
Prognostic and predictive biomarkers in renal cell carcinoma.
Target Oncol. 2010 Jun;5(2):85-94. doi: 10.1007/s11523-010-0143-8. Epub 2010 Jun 28.
9
Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma.
Cells. 2023 Dec 22;13(1):34. doi: 10.3390/cells13010034.
10
Role of imaging biomarkers for prognostic prediction in patients with pancreatic ductal adenocarcinoma.
Clin Radiol. 2020 Jun;75(6):478.e1-478.e11. doi: 10.1016/j.crad.2019.12.023. Epub 2020 Feb 6.
引用本文的文献
1
The prognostic and predictive value of vascular response parameters measured by dynamic contrast-enhanced-CT, -MRI and -US in patients with metastatic renal cell carcinoma receiving sunitinib.
Eur Radiol. 2018 Jun;28(6):2281-2290. doi: 10.1007/s00330-017-5220-2. Epub 2018 Jan 30.
2
Dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging noninvasive evaluation of vascular disrupting treatment on rabbit liver tumors.
PLoS One. 2013 Dec 23;8(12):e82649. doi: 10.1371/journal.pone.0082649. eCollection 2013.
本文引用的文献
1
Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course.
BMC Cancer. 2012 May 2;12:162. doi: 10.1186/1471-2407-12-162.
2
Optimisation of the tumour response threshold in patients treated with everolimus for metastatic renal cell carcinoma: analysis of response and progression-free survival in the RECORD-1 study.
Eur J Cancer. 2012 Jul;48(10):1512-8. doi: 10.1016/j.ejca.2012.01.027. Epub 2012 Feb 16.
3
Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot study.
Cancer Imaging. 2012 Jan 12;11(1):259-65. doi: 10.1102/1470-7330.2011.0032.
4
Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate.
Clin Cancer Res. 2011 Dec 15;17(24):7634-44. doi: 10.1158/1078-0432.CCR-11-1677. Epub 2011 Oct 28.
5
Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.
Urol Oncol. 2013 Oct;31(7):1283-91. doi: 10.1016/j.urolonc.2011.08.010. Epub 2011 Sep 29.
6
Course of size and density of metastatic renal cell carcinoma lesions in the early follow-up of molecular targeted therapy.
Urol Oncol. 2012 Sep;30(5):695-703. doi: 10.1016/j.urolonc.2010.10.011. Epub 2011 Aug 24.
7
Dynamic microbubble contrast-enhanced US to measure tumor response to targeted therapy: a proposed clinical protocol with results from renal cell carcinoma patients receiving antiangiogenic therapy.
Radiology. 2011 Aug;260(2):581-90. doi: 10.1148/radiol.11101893. Epub 2011 May 9.
8
Tumor size is a potential predictor of response to tyrosine kinase inhibitors in renal cell cancer.
Urology. 2011 Apr;77(4):831-5. doi: 10.1016/j.urology.2010.12.008. Epub 2011 Feb 12.
9
The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer.
Ann Oncol. 2011 May;22(5):1041-1047. doi: 10.1093/annonc/mdq564. Epub 2011 Jan 17.
10
Evaluation of response to multikinase inhibitor in metastatic renal cell carcinoma by FDG PET/contrast-enhanced CT.
Clin Nucl Med. 2010 Dec;35(12):918-23. doi: 10.1097/RLU.0b013e3181f9ddd9.
Zotero 插件